Introduction
============

Invasion and metastasis are key events in the aggressive biology of carcinomas and major obstacles to the treatment of malignancies. Proteolysis of the extracellular matrix (ECM) by matrix metalloproteinases (MMPs) is one of the most critical steps for growth, invasion, and metastasis of malignancies. The search for MMP-inducing factors in tumor cells led to the identification of EMMPRIN, whose name reflects its extracellular matrix metalloproteinase inducer activity[@R1]^,^[@R2] although MMP-9 was reported to be transcriptionally modulated by miR-211.[@R3]

EMMPRIN (also known as CD147, basigin, M6, and tumor cell-derived collagenase stimulatory factor) was purified from the surface of LX-1 lung carcinoma cells. The gene is localized to human chromosome 19p13.3, spans 12 169 bp, and encodes a 1566 bp transcript. The encoded protein is a glycosylated cell surface transmembrane protein that belongs to the immunoglobin superfamily. It is composed of a 185 amino acid (aa) extracellular region, a single 22 aa residue transmembrane domain, and a short 39 aa residue cytoplasmic domain.[@R1]^,^[@R4]^,^[@R5] The extracellular region contains 3 N-linked glycosylation sites, associated with 5--35 kDa glycosylation content, which is responsible for the MMP- stimulating activity. Co-transfection of EMMPRIN-expressing vectors with different tags and cross-linking experiments have suggested that the molecules could associate with each other on the plasma membrane, forming homo-oligomers in a *cis*-dependent manner via N-terminally located Ig-like domains.[@R6]^,^[@R7]

EMMPRIN has a broad tissue distribution, including activated T cells, differentiated macrophages, retinal pigment epithelium, endometrium, and normal human keratinocytes. Its expression is also frequently elevated in breast cancers, hepatocellular carcinomas, esophageal and cervical squamous cell carcinomas, non-small cell lung carcinomas, genitourinary, gastric, colorectal, prostate, and ovarian carcinomas. EMMPRIN is expressed in various forms, including highly (HG, 45--65 kDa) and lowly glycosylated (LG, 32--44 kDa) forms, as well as a core protein (approx 27 kDa). In vivo and in vitro evidences indicated that activated EMMPRIN might increase tumor invasion by inducing MMP synthesis in the surrounding stromal cells, including membrane type 1 and type 2 MMP, MMP-1, MMP-2, and MMP-3, and the endogenous activators of MMP-2.[@R8]^-^[@R22] Recently, EMMPRIN was reported to stimulate tumor angiogenesis by elevating vascular endothelial growth factor (VEGF) and MMP expression in neighboring fibroblasts and epithelial cells via microvesicle shedding.[@R12] It was reported that integrin α3β1 colocalized with EMMPRIN in human hepatoma cells and enhanced the effect of EMMPRIN on adhesion, invasion, and MMPs secretion. EMMPRIN overexpression also increases the expression of molecules downstream of integrins, including focal adhesion kinase (FAK), phospho-FAK, paxillin, and phospho-paxillin.[@R23]^,^[@R24] Upregulated EMMPRIN expression is induced by TGF-β coupled with epithelial--mesenchymal transition of hepatocellular carcinoma cells. The EMMPRIN expression is controlled by the cell survival PI3K/Akt/GSK3β signaling pathway and is directly regulated by the transcription factor Slug.[@R25] EMMPRIN overexpression in lung cancer cells upregulated the β-catenin signaling pathway, and silencing EMMPRIN inhibited β-catenin signaling, cell migration, proliferation, anchorage-independent growth, and tumor growth in a mouse xenograft model. Taken together, it is believed that EMMPRIN has a strong impact on the invasion and metastasis of malignant tumors.[@R26]

Ovarian cancer is the second leading cancer in women and the fifth leading cause of cancer-related deaths in women. More than 90% of ovarian cancers are classified as "epithelial" and are believed to arise from the ovarian epithelium, due to such risk factors as family history of ovarian carcinoma, mutation (p53, BRCA1, and BRCA2), epigenetic alteration (RUNX1 hypomethylation), estrogen replacement therapy, infertile women, times of pregnancy, endometriosis, and postmenopausal condition. Although several agents targeting the induction of apoptosis or autophagy, and the inhibition of proliferation are widely applied after surgical treatment, ovarian cancer is disproportionately deadly due to the usually late onset of symptoms.[@R27]^-^[@R32] Here, we investigated the effects and related mechanisms of EMMPRIN knockdown on the phenotypes of ovarian carcinoma cells. Additionally, the protein and mRNA expression of *EMMPRIN* was examined in ovarian normal tissue, benign and borderline tumors, primary and metastatic epithelial carcinomas. They were compared with the clinicopathological and prognostic parameters of tumors, including expression of Ki-67 protein.

Results
=======

As [Figure 1A and B](#F1AD){ref-type="fig"} indicates, OVCAR3, HO8910/pm, and ES-2 cells exhibited strong *EMMPRIN* mRNA expression by real-time PCR and western blot. EMMMPRIN was highly expressed in OVCAR3, HO8910/pm, and ES-2 cells with high glycosylation. However, there was no significance in the expression of EMMPRIN mRNA and protein between SKOV3 and its cisplatin-resistant SKOV3/DDP. To clarify the role of EMMPRIN, its expression was successfully knocked down in OVCAR3, SKOV3/DDP, and HO8910/pm cells by siRNA interference, evidenced by real-time PCR ([Fig. 1C](#F1AD){ref-type="fig"}), and western blot ([Fig. 1D](#F1AD){ref-type="fig"}). The transfectants showed a lower growth by CCK-8 ([Fig. 1E](#F1EG){ref-type="fig"}, *P* \< 0.05), no significantly decreased proliferation with cisplatin treatment ([Fig. 1F](#F1EG){ref-type="fig"}, *P* \> 0.05), G~1~ arrest by PI staining ([Fig. 1G](#F1EG){ref-type="fig"}, *P* \< 0.05) in comparison with the control or mock. There was an apoptosis-induced effect of *EMMPRIN* knockdown in the 3 transfectants, evidenced by Annexin V-FITC staining ([Fig. 1H](#F1HI){ref-type="fig"}, *P* \< 0.05). At the same time, we also found the transfectants exhibited lower migration by wound healing ([Fig. 1I](#F1HI){ref-type="fig"}, *P* \< 0.05) and slower invasion by transwell chamber assay ([Fig. 1J](#F1JL){ref-type="fig"}, *P* \< 0.05) than the control and mock cells. Additionally, *EMMPRIN* siRNA transfectants showed reduced expression of *Wnt5a*, *Akt*, *p70s6k, Bcl-xL*, *survivin, VEGF*, and *MMP-9,* compared with the control and mock cells by real-time PCR ([Fig. 1K](#F1JL){ref-type="fig"}) and western blot ([Fig. 1L](#F1JL){ref-type="fig"}). There was no difference in *GST-π* and *MDR* expression between the transfectants, mock, and control cells (data not shown) by real-time PCR.

![**Figure 1A--D.** The effects of *EMMPRIN* knockdown on the aggressive phenotypes of ovarian carcinoma cells. The mRNA and protein expressions of EMMPRIN were screened in ovarian carcinoma cells (OVCAR3, SKOV3, SKOV3/DDP, HO8910, HO8910/pm, HO8910, ES-2, and CAOV3) by real-time PCR (**A**) and western blot (**B**), respectively. EMMPRIN proteins were classified into Core protein (27kDa), less-glycosylated (\~32--44 kDa, LG) and highly glycosylated form (\~45--65 kDa, HG). After transfection of *EMMPRIN* siRNA, its expression was reduced in OVCAR3, SKOV3/DDP, and HO8910/pm cells by real-time RT-PCR (**C**) and western blot (**D**) compared with control (CTR), and mock cells. The transfectants showed lower growth by CCK-8 (**E**), no significantly lower proliferation with DDP treatment by CCK-8 (**F**), G~1~ arrest by PI staining (**G**), higher apoptosis by Annexin V staining (**H**), lower migration by wound healing (**I**), and weaker invasion by transwell (**J**) than the control and mock cells. After the treatment of *EMMPRIN* siRNA, there was reduced expression of *Wnt5a*, *Akt*, *p70s6k, Bcl-xL*, *survivin, VEGF*, and *MMP-9* at both mRNA and protein levels in OVCAR3, SKOV3/DDP, and HO8910/pm cells by real-time PCR (**K**) and western blot (**L**). \* *P* \< 0.05. Results are representative of 3 different experiments, and data are expressed as mean ± standard deviation with the control as "1".](cc-12-2899-g1AD){#F1AD}

![See [**Figure 1A--D**](#F1AD){ref-type="fig"} legend.](cc-12-2899-g1EG){#F1EG}

![**Figure 1H and I.** See [**Figure 1A--D**](#F1AD){ref-type="fig"} legend.](cc-12-2899-g1HI){#F1HI}

![**Figure 1J--L.** See [**Figure 1A--D**](#F1AD){ref-type="fig"} legend.](cc-12-2899-g1JL){#F1JL}

As shown in Figure 2, *EMMPRIN* mRNA level was higher in ovarian borderline tumor and carcinoma than normal ovary and benign tumors ([Fig. 2A and B](#F2AJ){ref-type="fig"}, *P* \< 0.05) by real-time RT-PCR. High-staging carcinoma showed more *EMMPRIN* mRNA expression than low-staging one ([Fig. 2C](#F2AJ){ref-type="fig"}, *P* \< 0.05). Decreased expression of *EMMPRIN* mRNA was observed in well- and moderately-differentiated carcinoma in comparison with poorly-differentiated carcinoma ([Fig. 2D](#F2AJ){ref-type="fig"}, *P* \< 0.05). However, there was no correlation between *EMMPRIN* mRNA expression and pathological classification ([Fig. 2E](#F2AJ){ref-type="fig"}, *P* \> 0.05). According to western blot ([Fig. 2F](#F2AJ){ref-type="fig"}), core protein expression level was significantly higher in borderline tumor and carcinoma than normal ovary and benign tumors ([Fig. 2G](#F2AJ){ref-type="fig"}, *P* \< 0.05), whereas HG form was more expressed in carcinoma than normal ovary ([Fig. 2K](#F2KR){ref-type="fig"}, *P* \< 0.05), and metastatic than primary carcinoma ([Fig. 2O](#F2KR){ref-type="fig"}, *P* \< 0.05). There was greater expression of the 3 EMMPRIN forms in III-IV carcinomas in comparison with I-II ones (*P* \< 0.05, [Fig. 2H, L, and P](#F2AJ){ref-type="fig"}). Additionally, higher HG EMMPRIN expression was observed in poorly-differentiated carcinomas than well- and moderately- differentiated ones ([Fig. 2Q](#F2KR){ref-type="fig"}, *P* \< 0.05).

![**Figure 2A--J.***EMMPRIN* mRNA and protein expression in ovarian carcinogenesis and its correlation with clinicopathological features of ovarian carcinoma. *EMMPRIN* mRNA was quantified in ovarian normal tissue (No, n = 17), benign (Be, n = 10) and borderline (Bo, n = 6) tumor, primary carcinoma (Ca, n = 66), and metastatic carcinoma in omentum (Om, n = 21) by real-time PCR. *EMMPRIN* mRNA expression level was significantly higher in ovarian borderline tumors and carcinoma than in ovarian normal tissue and benign tumors (**B**), positively with FIGO staging (**C**) inversely linked to differentiation degree of ovarian carcinoma (**D**), but not to subtyping (**E**). Tissue lysate of ovarian normal tissue (n = 11), benign (n = 12), and borderline (n = 9) tumor, primary carcinoma (n = 60), and metastatic carcinoma in omentum (n = 16) was loaded and probed with anti-EMMPRIN antibody (27--65 kDa, panel 1) with GAPDH (37 kDa, panel 2) as an internal control (**F**) by western blot. According to the molecular weight, EMMPRIN proteins were classified and respectively subjected to densitometric analysis in core protein (27 kDa, **G--J**), less-glycosylated (\~32--44 kDa, LG, **K--N**) and highly glycosylated form (\~45--65 kDa, HG**, O--R**). Normal ovary lowly expressed its core form, in comparison to the borderline tumors and carcinoma (**G**). Its HG form was less expressed in normal tissue than in primary carcinoma that showed less HG EMMPRIN expression than metastatic carcinoma (**O**). There appeared higher expression of core (**H**), LG (**L**), and HG (**P**) EMMPRIN proteins in I/II than III/IV ovarian carcinomas respectively. The poorly-differentiated carcinoma showed more HG EMMPRIN expression than the well- or moderately-differentiated carcinoma (**Q**). \**P* \< 0.05.](cc-12-2899-g2AJ){#F2AJ}

![**Figure 2K--R.** See [**Figure 2A--J**](#F2AJ){ref-type="fig"} legend.](cc-12-2899-g2KR){#F2KR}

Immunostaining revealed strong EMMPRIN expression in the cytoplasm and membrane of serous adenoma, serous and mucinous borderline tumor, serous, and mucinous adenocarcinoma, endometriod carcinoma, serous adenocarcinoma in omentum, but not or very weak in normal fiber cells and in fallopian tube ([Fig. 3A--K](#F3){ref-type="fig"}). As shown in [Table 1](#T1){ref-type="table"}, EMMPRIN protein expression was detectable in ovarian normal tissue (8%, 2/25), benign tumor (26.7%, 4/15), borderline tumor (60.0%, 15/25), carcinoma (64.5%, 156/242), and metastatic carcinoma in omentum (76.8%, 43/56), respectively. Statistically, EMMPRIN expression was stronger in borderline tumor and primary carcinoma than that in ovarian normal tissue and benign tumors (*P* \< 0.05), whereas metastatic carcinoma in was stronger omentum than primary carcinoma (*P* \< 0.05). EMMPRIN expression was positively correlated with FIGO staging, dedifferentiation and Ki-67 expression (*P* \< 0.05), but not with age or histological classification (*P* \> 0.05, [Table 2](#T2){ref-type="table"}).

![**Figure 3.** EMMPRIN expression and its prognostic significance in ovarian samples by immunohistochemistry. Note: EMMPRIN protein is distributed to the membrane and cytoplasm, while Ki-67 protein to the nucleus. EMMPRIN was not expressed in normal fiber cells (**A**) and in fallopian tube (**B**), but strongly in serous (**C**) adenoma, serous (**D and E**), and mucinous (**F**) borderline tumor, serous (**G and H**) and mucinous (**I**) adenocarcinoma, endometriod carcinoma (**J**), serous adenocarcinoma in omentum (**K**). Furthermore, Ki-67 protein showed higher expression in ovarian adenocarcinoma (**L**). Kaplan--Meier analysis indicated that EMMPRIN expression was positively correlated with lower cumulative (**M**) and relapse-free (**N**) survival rate of patients with ovarian carcinomas.](cc-12-2899-g3){#F3}

###### **Table 1.** EMMPRIN protein expression in ovarian epithelial carcinogenesis

  Groups                            *n*   EMMPRIN protein expression                              
  --------------------------------- ----- ---------------------------- ------- -------- --------- -----------
                                          −                            **+**   **++**   **+++**   **PR(%)**
  Normal ovary                      25    23                           1       1        0         8.0
  Ovarian benign tumors             15    11                           1       3        0         26.7
  Ovarian borderline tumor          25    10                           4       4        7         60.0\*
  Ovarian carcinoma                 242   86                           46      47       63        64.5\*
  Metastatic carcinoma in omentum   56    13                           8       12       23        76.8\*\*

Abbreviation: PR, positive rate. \*Compared with normal ovary and ovarian benign tumors, *P* \< 0.01; \*\*Compared with primary carcinoma, *P* \< 0.05.

###### **Table 2.** Relationship between EMMPRIN protein expression and clinicopathological features of ovarian carcinoma

  -----------------------------------------------------------------------------------------------------------------------
  Clinicopathological\          *n*   EMMPRIN protein expression                                          
  features                                                                                                
  ----------------------------- ----- ---------------------------- ------- -------- --------- ----------- ---------------
                                      −                            **+**   **++**   **+++**   **PR(%)**   ***P* value**

  Age(years)                                                                                              0.774

    \<56                        120   46                           20      21       33        61.7         

    ≥56                         122   40                           26      26       30        67.2         

  Pathological classification                                                                             0.229

    Serous adenocarcinoma       177   63                           36      34       44        64.4         

    Mucinous adenocarcinoma     27    13                           3       5        6         51.9\*       

    Miscellaneous subtypes      38    10                           7       8        13           73.7      

  FIGO staging                                                                                            0.027

  I-II                          94    47                           12      17       18        50.0         

  III-IV                        148   47                           34      30       37        68.2         

  Differentiation                                                                                         0.032

  Well-differentiated           58    27                           13      6        12        53.4         

  Moderately-differentiated     98    36                           16      22       24        63.3         

  Poorly-differentiated         86    23                           17      19       27        73.3         

  Ki-67 expression                                                                                        0.040

    −                           31    9                            10      9        3         71.0         

    +                           23    11                           3       5        4         52.2         

    ++                          25    6                            6       1        12        76.0         

    +++                         25    3                            8       4        10        88.0         

  Serum Ca125 level(U/mL)                                                                                 0.303

    \<500                       44    20                           9       7        8         54.5         

    ≥500                        48    18                           7       12       11        62.5         
  -----------------------------------------------------------------------------------------------------------------------

\*Compared with other pathological subtypes, *P* \< 0.01.

Follow-up information was available on 88 ovarian carcinoma patients for periods ranging from 1 to 103 months (median = 52 mo, there were, altogether, 98 cases, while 10 of them lost follow-up). Survival curves for ovarian carcinomas were stratified according to EMMPRIN protein expression ([Fig. 3M and N](#F3){ref-type="fig"}). Univariate analysis using Kaplan--Meier method indicated an inverse relationship between EMMPRIN expression and cumulative or relapse-free survival rate of patients with ovarian carcinoma (*P* \< 0.05). Multivariate analysis using Cox proportional hazard model indicated that only FIGO staging was an independent prognostic factor for overall survival of the ovarian carcinoma patients (*P* \< 0.05, [Table 3](#T3){ref-type="table"}).

###### **Table 3.** Multivariate analysis of clinicopathological variables for the overall survival of the patients with ovarian carcinomas

  Clinicopathological parameters        Overall survival            Relapse-free survival                               
  ------------------------------------- --------------------------- ----------------------- --------------------------- ---------------
                                        **Relative risk (95%CI)**   ***P* value**           **Relative risk (95%CI)**   ***P* value**
  Age (≥56 y)                           1.949(0.954--3.982)         0.067                   1.716(0.949--3.102)         0.074
  Pathological subtypes                 1.063(0.428--2.641)         0.895                   0.882(0.415--1.874)         0.744
  FIGO staging(III-IVI)                 2.671(1.004--7.105)         0.049                   2.071(0.958--4.479)         0.064
  Differentiation degree (poorly)       1.579(0.762--3.269)         0.219                   1.082(0.602--1.945)         0.791
  EMMPRIN protein expression (+\~+++)   1.542(0.763--3.232)         0.251                   1.625(0.882--2.993)         0.120
  Remanant foci size (≥1 cm)            1.931(0.862--4.512)         0.129                   1.431(0.717--2.857)         0.309
  Serum CA125 level (≥500)              0.976(0.494--1.928)         0.944                   1.147(0.648--2.033)         0.638

Abbreviation: CI, confidence interval.

Discussion
==========

The interactions between tumor cells and microenvironment orchestrate angiogenesis, growth, dissemination, and metastasis of tumors. The cross-talk between tumor cells and adjacent stromal cells via paracrine and autocrine signals participates in tumor immune system avoidance, spreading, and angiogenesis. These biological events are mediated by a number of soluble and membrane molecules, including growth factors, soluble Fas, Fas ligand, soluble MMPs, soluble VEGF, EMMPRIN, and ADAM9.[@R13]^,^[@R21]^,^[@R22]^,^[@R34]^-^[@R37]

Numerous studies have indicated that the presence and modulation of EMMPRIN might play some roles in normal physiological processes.[@R4]^,^[@R38] In the present study, EMMPRIN protein expression was seldom or weakly observed in ovarian fiber cells and fallopian tube. Gabison et al.[@R4] reported EMMPRIN to be predominantly expressed in corneal epithelium, but markedly elevated in the anterior stroma of ulcerated corneas. Therefore, we speculate that EMMPRIN might be involved in stromal remodeling and epithelial repair of ovarian epithelial tissue. Ectopic EMMPRIN overexpression in relatively less aggressive carcinoma cell lines results in an acquired ability to form large and malignant tumors with a more invasive phenotype in nude mice.[@R39] In this study, we detected stronger EMMPRIN expression in carcinomas and borderline tissue than benign tumor and normal ovary at both mRNA and protein levels, in line with other malignancies.[@R8]^-^[@R16]^,^[@R18]^-^[@R22] Additionally, there was higher expression of core and HG EMMPRIN in ovarian carcinoma than normal ovary, suggesting their important role in ovarian carcinogenesis. Caveolin-1 partly associates with EMMPRIN and forms caveolin-1-LG-EMMPRIN complex on the cell surface during glycosylation procedure.[@R40] Taken together, it is suggested that the alteration in the expression and the protein glycosylation of EMMPRIN might play an essential role in ovarian carcinogenesis.

Elevated EMMPRIN expression has also been shown to correlate with the progression of various malignancies.[@R4]^,^[@R8]^-^[@R12]^,^[@R21]^,^[@R22] Here, it was found that *EMMPRIN* mRNA, in situ EMMPRIN expression, the expression level of core, LG, and HG EMMPRIN was positively linked to FIGO staging of ovarian carcinoma. Metastatic carcinoma showed higher EMMPRIN glycosylation level than primary carcinoma. These findings suggested that mRNA, protein expression, and glycosylation level of EMMPRIN might be involved in the progression of ovarian carcinoma and be considered as a potential marker for the aggressiveness of ovarian carcinoma. Additionally, higher mRNA expression and high glycosylation were found in poorly differentiated carcinoma, opposite to the finding of gastric carcinoma,[@R21] indicating that they might have impact on the differentiation of ovarian carcinoma cells. The positive correlation between EMMPRIN and Ki-67 expression was found in ovarian carcinoma, consistent with a previous report.[@R22] Experimentally, blockade of host EMMPRIN expression, but not cancer cell-derived EMMPRIN, suppresses tumor growth in human colon cancer xenografts.[@R39] Here, we also observed that *EMMPRIN* knockdown could cause the low proliferation, G~1~ arrest and low migration and invasion of 3 ovarian carcinoma cells, supporting the promoting effects of EMMPRIN expression on proliferation, migration, and invasion of ovarian carcinoma cells.

Yang et al.[@R40] found that EMMPRIN expression rendered breast carcinoma cells resistant to anoikis, a form of apoptosis triggered by a lack of or improper cell--matrix interactions, mediated by downregulation of the pro-apoptotic BH3-only protein, Bim, through a MAP kinase-dependent pathway. Our data showed that *EMMPRIN* siRNA treatment promoted apoptosis with the deceased expression of anti-apoptotic gene and encoding proteins (*Bcl-xL* and *survivin*). Marieb et al.[@R10] documented that upregulated EMMPRIN expression stimulated hyaluronan production by elevating hyaluronan synthases, which had been linked to anchorage-independent growth of cancer cells. Because Wnt5a, VEGF, and MMP-9 are involved in invasion or metastasis of several cancers,[@R41]^,^[@R42] ovarian carcinoma cells with *EMMPMRIN* knockdown exhibited weak ability to migrate and invade by downregulating these 3 molecules. In agreement with our finding, a large body of evidence indicates that increased soluble EMMPRIN released from cancer cells can stimulate the MMP synthesis and activation of surrounding stromal cells, promoting the progression of tumors.[@R4]^,^[@R8]^-^[@R12] Recently, Tang et al.[@R43] found that the elevation of MMPs mediated by EMMPRIN could result in more proteolytic cleavage of membrane-associated EMMPRIN, forming a positive feedback between tumor--stroma interaction. Furthermore, EMMPRIN transfection of tumor cells, or treating tumor cells with the recombinant protein, increased expression of MMPs.[@R44] These findings support the opinion that EMMPRIN might enhance tumor growth and invasion of ovarian carcinoma by disrupting apoptotic and invasive events.

The subpopulations of tumor cell lines constitutively expressing high levels of cell-surface EMMPRIN exhibit cancer stem-like cell properties, such as much greater invasiveness, anchorage-independent growth, spheroid formation, and drug resistance.[@R45] EMMPRIN induces unfolded protein response to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma.[@R46] There was also a decrease of monocarboxylate transporter 1 expression in the invasion and metastasis potential of pancreatic cancer cells, as well as increased chemosensitivity to gemcitabine in Panc-1 cells.[@R47] Membranous EMMPRIN expression, but not the overall EMMPRIN expression, was associated with poor response to cisplatin-based chemotherapies and a poor prognosis in advanced patients with non-small-cell lung carcinoma.[@R48] Silencing EMMPRIN increased the proliferation-inhibiting effect of cisplatin to lung cancer A549/DDP,[@R42] laryngeal carcinoma Hep2,[@R49] and gastric carcinoma SG7901[@R50] cells. However, we found no difference in *EMMPRIN* expression between ovarian carcinoma SKOV3 and SKOV3/DDP. The EMMPRIN downregulation didn't cause the higher sensitivity to cisplatin and the alteration in the expression of drug resistance genes (*GST-π* and *MDR*) in OVCAR3, SKOV3/DDP, and HO8910/PM cells. These data indicated that EMMPRIN expression might not be linked to the chemosensitivity to cisplatin in ovarian cancer cells.

Although Ishibashi et al.[@R9] reported that EMMPRIN expression was not associated with the recurrence-free survival of esophageal squamous cell carcinoma, we found that EMMPRIN expression might be used as a maker to indicate the worse prognosis of gastric carcinoma, albeit not an independent factor.[@R21] Reportedly, positive EMMPRIN staining was correlated significantly with decreased tumor-specific survival of human seminoma,[@R51] medulloblastoma,[@R52] bladder cancer,[@R53] and differentiated thyroid carcinoma[@R54] as an independent prognosticator. In hepatocellular carcinoma, the patients with EMMPRIN expression had poorer tumor recurrence-free survival than those with negative expression of EMMPRIN.[@R55] In the present study, we analyzed the relation between EMMPRIN expression and survival of 98 patients with ovarian carcinoma. The results revealed a negative link between EMMPRIN expression and relapse-free or cumulative survival rate of ovarian carcinoma patients. The multivariate analysis demonstrated that only FIGO staging was an independent prognostic factor for overall ovarian carcinomas. These findings suggested that EMMPRIN protein expression was closely linked to the adverse prognosis of the patients with ovarian carcinoma, albeit not independent.

In summary, the upregulated expression and protein glycosylation of EMMPRIN might contribute to pathogenesis, differentiation, and progression of ovarian epithelial carcinoma, possibly by modulating cellular events such as proliferation, cell cycle, apoptosis, migration, and invasion. It could thus be considered as a good marker to predict tumorigenesis and aggressiveness of ovarian epithelial carcinoma.

Materials and Methods
=====================

Cell culture and transfection
-----------------------------

Ovarian carcinoma cell lines, CAOV-3 (serous adenocarcioma), OVCAR3 (serous cystic adenocarcinoma), SKOV-3 (serous papillary cystic adenocarcinoma), cisplatin-resistant SKOV3 (SKOV3 /DDP), HO8910 (serous cystic adenocarcinoma), highly-invasive HO8910 (HO8910/pm), and ES-2 (clear cell carcinoma), were purchased from ATCC. They were maintained in RPMI 1640 (ES-2, H08910, H08910/pm, OVCAR3, and SKOV3/DDP), DMED (CAOV3), and McCoy 5A(SKOV3) medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 100 μg/mL streptomycin in a humidified atmosphere of 5% CO~2~ at 37 °C. The cells were transfected with *EMMPRIN* siRNA at 70% confluence 24 h after seeding on dishes according to the manufacturer's instructions (QIAGEN). The target EMMPRIN sequences were GGUCCUUGCCCUUUGUGGAdT dT (sense) and UCC ACAAAGGGCAAGGACCdTdT (antisense). The negative siRNA control sequences were UUCUCCG AACGUGUCAC GUTT (sense) and ACGUGACACG UUCGGAGAATT (anti-sense). The cells were harvested by centrifugation, rinsed with phosphate buffered saline (PBS), and subjected to total RNA or protein extraction.

Proliferation assay
-------------------

Cell counting Kit-8 (CCK-8) was employed to determine the number of viable cells. In brief, 2.5 × 10^3^ cells/well were seeded on 96-well plate and allowed to adhere. At different time points, 10 μL of CCK-8 solution was added into each well of the plate, and the plates were incubated for 3 h in the incubator and measured at 450 nm.

Cell cycle analysis
-------------------

The cells were trypsinized, collected, washed by PBS twice, and fixed in cold 10 mL ethanol for more than 2 h. Then, the cells were washed by PBS twice and incubated with 1 mL RNase (0.25 mg/mL) at 37 °C for 1 h. The cells were pelleted and resuspended in propidium iodide (PI) at a concentration of 50 µg/mL and incubated at 4 °C in the dark for 30 min. Finally, flow cytometry was employed to examine PI signal.

Apoptosis assay by flow cytometry
---------------------------------

Flow cytometry was performed with 7-amino-actinomycin (7-AAD) and FITC-labeled annexin V (BD PharMingen) to detect phosphatidylserine externalization as an endpoint indicator of early apoptosis according to the manufacturer's instructions.

Wound-healing assay
-------------------

Cells were seeded at a density of 1.0 × 10^6^ cells/well in 6-well culture plates. After they had grown to confluence, the cell monolayer was scraped with a pipette tip to create a scratch, washed by PBS 3 times, and cultured in the FBS-free medium. Cells were photographed at 24 h, and the scratch area was measured using Image software.

Cell invasion assays
--------------------

For invasive assay, 2.5 × 10^5^ cells were resuspended in serum-free RPMI 1640, and seeded in the matrigel-coated insert on the top portion of the chamber (BD Bioscience, 354481). The lower compartment of the chamber contained 10% v/v FBS as a chemoattractant. After incubated at 37 °C and 5% CO~2~ for 24 h, cells on the membrane were scrubbed, washed with PBS, fixed in 100% methanol, and stained with Giemsa dye for the measurement.

Subjects
--------

Between January 2005 and December 2011, ovarian normal tissue, benign and borderline tumors, primary epithelial carcinomas, and their metastatic carcinomas in omentum were collected from surgical resection at Department of Gynecology, The First Hospital Affiliated of China Medical University. The average age at surgery was 51.2 y (range 20--81 y). The parts of ovarian tissues were subjected to the routine preparation of pathological block. Some samples were frozen immediately in liquid nitrogen and stored at −80°C until use. None of the patients underwent chemotherapy, radiotherapy or adjuvant treatment before surgery. We followed up the patients by consulting their case documents and by telephone. Informed consent was obtained from all subjects, and the study protocol was approved by China Medical University Ethics Committee.

Real-time PCR
-------------

Total RNA was extracted from ovarian carcinoma cell lines and ovarian tissue using Trizol (Takara). Two micrograms of total RNA was subjected to cDNA synthesis using the AMV reverse transcriptase and random primer (Takara). According to the GenBank, oligonucleotide primers for PCR were shown in [Table S1](#SUP1){ref-type="supplementary-material"}. Real-time PCR amplification of cDNA was performed in 20 µL mixtures according to the protocol of SYBR Premix Ex Taq^™^ II kit (Takara) with GAPDH as an internal control.

Western blot
------------

Protein was extracted in RIPA lysis buffer and its concentration was determined by protein assay kit (Bio-Rad Laboratories). The denatured protein was separated on a sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred to Hybond membrane, which was then blocked overnight in 5% skim milk in Tris Buffered Saline with Tween 20 (TBST, 10 mM TRIS-HCl, 150 mM NaCl, 0.1% Tween 20). For immunoblotting, the membrane was incubated for 1 h with an antibody against EMMPRIN (Novocastra Laboratories Ltd; 1:100), Wnt5a (Santa Cruz), phosphorylated p70 s6k (T421/s424, Cell Signaling), Akt (Santa Cruz), Bcl-xL (Santa Cruz), survivin (Santa cruz), VEGF (Santa Cruz), or MMP-9 (Santa Cruz) protein. The blot was then was then rinsed with TBST, and incubated with anti-mouse, anti-rabbit, or anti-goat IgG conjugated to horseradish peroxidase (DAKO, 1:1000) for 1 h. Bands were visualized with Fuji 4000 using ECL detection reagents (Santa Cruz). After the detection, membranes were washed with WB Stripping Solution (pH2--3, Nacalai) for 20 min and treated as described above except with mouse GAPDH antibody (Sigma, 1:10 000) as an internal control. Densitometric quantification of EMMPRIN protein in ovarian samples was performed with an internal control of GAPDH using Scion Image software (Scion Corporation).

Pathology, tissue microarray (TMA), and immunohistochemistry (IHC)
------------------------------------------------------------------

All tissues were fixed in 10% neutral formalin, embedded in paraffin and sections cut at 4 μm. These sections were stained by hematoxylin-and-eosin (HE) to confirm their histological diagnosis and other microscopic characteristics. Each ovarian carcinoma was evaluated according to the international Federation of Gynecology and Obstetrics (FIGO) staging system. Histological architecture of ovarian carcinoma was expressed in terms of WHO classification.

Representative areas of solid tumors were identified in HE stained sections of the selected tumor cases, and a 2 mm diameter tissue core was punched out from each donor block and transferred to a recipient block with a maximum of 48 cores using a Tissue Microarrayer (AZUMAYA KIN-1). Four-μm-thick sections were cut from the recipient block and transferred to poly-lysine-coated glass slides. HE staining was performed on TMA for confirmation of tumor tissue.

Consecutive sections were deparaffinized with xylene, rehydrated with alcohol, and subjected to antigen retrieval by irradiation in target retrieval solution (TRS, DAKO) for 15 min with a microwave oven (Oriental Rotor Lmt Co). Five percent bovine serum albumin was then applied for 1 min to prevent non-specific binding. The sections were incubated with primary antibodies for 15 min, then treated with anti-mouse or anti-rabbit Envison-PO (DAKO) antibody for 15 min. All incubations were performed in a microwave oven to allow intermittent irradiation as described previously.[@R33] After each treatment, the slides were washed 3 times with TBST for 1 min. Mouse anti-EMMPRIN (Novocastra; 1:50) or rabbit anti-Ki-67 (DAKO; 1:50) antibodies were employed for the detection of the respective proteins. Binding sites were visualized with 3, 3′-diaminobenzidine and counterstained with Mayer's hematoxylin. Omission of the primary antibody was used as a negative control.

The immunoreactivity to EMMPRIN was localized in the cytoplasm and membrane, and Ki-67 in the nucleus ([Fig. 3](#F3){ref-type="fig"}). One hundred cells were randomly selected and counted from 5 representative fields of each section blindly by 2 independent observers (Zhao Y and Zheng HC). The inconsistent data were confirmed by both persons until final agreements were reached. The expression positivity was graded and counted as follows: 0 = negative; 1 = 1--50%; 2 = 50--74%; 3 ≥ 75%. The staining intensity score was graded as follows: 1, weak; 2, intermediate; 3, strong. The scores for EMMPRIN or Ki-67 positivity and staining intensity were multiplied to obtain a final score, which determines their expression as (− = 0; + = 1--2; ++ = 3--4; +++ = 6--9).

Measurement of CA125
--------------------

Serum CA125 was determined by Quantitative Chemiluminescence Immunoassay Kit (Gentaur, France). Briefly, 50 μL of standard (0--1000 U/ml), specimens, and controls was dispensed into appropriate wells. Then, 100 μL of Enzyme Conjugate Reagent was added into each well, gently mixed, and incubated the plate at room temperature for 60 min. The microtiter wells were rinsed and flicked with wash buffer. After that, residual water droplets were removed by striking the well sharply onto absorbent paper. Finally, 100 μL hemiluminescence substrate solution was dispensed into each well, mixed gently, and subjected to absorbance determination.

Statistical analysis
--------------------

Statistical evaluation was performed using Spearman correlation test to analyze the rank data, and Mann--Whitney U to differentiate the means of different groups. Kaplan--Meier survival plots were generated, and comparisons were made with log-rank statistic. Cox's proportional hazards model was employed for multivariate analysis. *P* \< 0.05 was considered as statistically significant. SPSS 10.0 software was employed to analyze all data.

Supplementary Material
======================

This study was supported by Shenyang Outstanding Talent Foundation of China; Shenyang Science and Technology Grant (F11-264-1-10; F12-277-1-01); A Project Supported by Scientific Research Fund of Liaoning Provincial Education Department (L2010633); Liaoning Science and Technology Grant (2009225008-11); Natural Scientific Foundation of China (No. 81172371; 81202049); Grant-in aid for Scientific Research from the Ministry of Education, Culture, Sports and Technology of Japan (23659958).

Previously published online: [www.landesbioscience.com/journals/cc/article/25950](http://www.landesbioscience.com/journals/cc/article/25950/)

No potential conflicts of interest were disclosed.
